Mirati Therapeutics Stock Forecast, Price & News

Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MRTX shares have increased by 200.6% and is now trading at $232.54.
View which stocks have been most impacted by COVID-19.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Mirati Therapeutics or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Mirati Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mirati Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Mirati Therapeutics.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) issued its earnings results on Wednesday, November, 4th. The biotechnology company reported ($1.96) EPS for the quarter, topping the Zacks' consensus estimate of ($2.03) by $0.07. The biotechnology company had revenue of $11.40 million for the quarter, compared to analysts' expectations of $0.21 million. Mirati Therapeutics had a negative net margin of 10,983.84% and a negative return on equity of 60.10%. Mirati Therapeutics's revenue was up 1053.8% compared to the same quarter last year.
View Mirati Therapeutics' earnings history.

15 equities research analysts have issued 1-year price targets for Mirati Therapeutics' shares. Their forecasts range from $116.00 to $267.00. On average, they anticipate Mirati Therapeutics' stock price to reach $215.36 in the next year. This suggests that the stock has a possible downside of 7.4%.
View analysts' price targets for Mirati Therapeutics.

Mirati Therapeutics saw a drop in short interest in October. As of October 30th, there was short interest totaling 3,740,000 shares, a drop of 13.6% from the October 15th total of 4,330,000 shares. Based on an average daily volume of 522,400 shares, the short-interest ratio is presently 7.2 days.
View Mirati Therapeutics' Short Interest.

Some companies that are related to Mirati Therapeutics include Astellas Pharma (ALPMY), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), BeiGene (BGNE), Genmab A/S (GMAB), Genmab A/S (GNMSF), UCB (UCBJF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Royalty Pharma (RPRX), Catalent (CTLT), Horizon Therapeutics Public (HZNP), CureVac (CVAC), Alnylam Pharmaceuticals (ALNY) and Ono Pharmaceutical (OPHLF).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Square (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Mirati Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (6.83%), BlackRock Inc. (7.66%), Sands Capital Management LLC (2.65%), State Street Corp (2.16%), UBS Asset Management Americas Inc. (1.29%) and EcoR1 Capital LLC (0.92%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Henry J Fuchs, Isan Chen, Jamie A Donadio, Ltd Braslyn, Michael G Grey and Venbio Select Advisor Llc.
View institutional ownership trends for Mirati Therapeutics.

MRTX stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Lord Abbett & CO. LLC, State Street Corp, Clough Capital Partners L P, Sphera Funds Management LTD., BlackRock Inc., Polar Capital LLP, and Polar Capital LLP. Company insiders that have sold Mirati Therapeutics company stock in the last year include Boxer Capital, Llc, Charles M Baum, Craig A Johnson, Henry J Fuchs, Isan Chen, and Ltd Braslyn.
View insider buying and selling activity for Mirati Therapeutics.

MRTX stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Wells Fargo & Company MN, EcoR1 Capital LLC, Charles Schwab Investment Management Inc., UBS Asset Management Americas Inc., Federated Hermes Inc., Handelsbanken Fonder AB, and Assenagon Asset Management S.A..
View insider buying and selling activity for Mirati Therapeutics.

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRTX stock can currently be purchased for approximately $232.54.

Mirati Therapeutics has a market capitalization of $11.69 billion and generates $3.34 million in revenue each year. The biotechnology company earns $-213,260,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Mirati Therapeutics employs 111 workers across the globe.

The official website for Mirati Therapeutics is www.mirati.com.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]